Gilead Sciences, Inc. (NASDAQ:GILD) is considered one of the most profitable healthcare stocks to buy. UBS recently raised the price target on GILD from $145 to $155, implying nearly 12% upside. BMO Capital also increased its target to $150 and reiterated an Outperform rating, citing strong momentum in the company’s HIV business.

UBS analysts believe in the strong performance of the U.S. Pharmaceuticals and Biotechnology group due to appealing valuations, light positioning, and sustained M&A activity. Despite worries about conservative guidance, inexpensive valuations are expected to attract positive money flows into the sector. GILD is a California-based biopharmaceutical company founded in 1987, specializing in medicines for various conditions like HIV/AIDS, COVID-19, and viral hepatitis.

Investors looking for AI stocks with greater upside potential and less downside risk may find better options than GILD. While GILD offers investment potential, certain AI stocks may present more attractive opportunities. For those interested in undervalued AI stocks with potential benefits from Trump-era tariffs and the onshoring trend, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook